NASH FibroSure
NASH FibroSure-994
NASH FibroSure
994
LAB994
MSO
Fatty liver disease
Nonalcoholic fatty liver disease
Noninvasive liver biopsy
Steatohepatitis
Nonalcoholic fatty liver disease
Noninvasive liver biopsy
Steatohepatitis
This test is a noninvasive assessment of liver status in patients with nonalcoholic fatty liver disease (NAFLD). Quantitative results of 10 biochemicals in combination with age, gender, height, and weight are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) of liver fibrosis (Metavir F0-F4), hepatic steatosis (0.0-1.0, S0-S3), and nonalcoholic steatohepatitis (NASH) (0.0-0.75, N0-N2). The absence of steatosis (S<0.38) precludes the diagnosis of NASH.
Patient should be fasting for at least eight hours prior to sample collection.
Serum
3.5 mL
2.0 mL
Immediatley following collection, mix sample by inverting 5 times
- Allow sample to clot fpr a minimum of 30 minutes
- Spin
- Transfer serum to a Screw cap transfer vial/tube (Mayo T465), labelled as serum, within two (2) hours of sample collection
- Freeze
- Allow sample to clot
- Spin
- Transfer serum to a Screw cap transfer vial/tube (Mayo T465), labelled as serum, within two (2) hours of sample collection
- Freeze
- Patient's age
- Patient's gender
- Patient height
- Patient weight
Frozen (preferred) - 7 days
Refrigerated - 72 hours
- Gross hemolysis
- Gross lipemia
- Improper labeling
- Nonfasting specimen
- Patient <14 years of age
LabCorp Burlington (550140): R-NX
Mo - Fr
3 - 6 days
An interpretive report will be provided
11/11/2016
05/24/2019